Goat anti human PAI-1 antibody
recognizes human Plasminogen activator inhibitor 1 (PAI-1), also known as Serpin E1. PAI-1 is a 402 amino acid }45kDa serine protease inhibitor epitope within the internal region of human Serpin E1. PAI-1 (Serpin E1) is a 45kD serine protease inhibitor and the principle inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA)
PAI-1 is present in plasma, platelets and endothelial cells, is expressed at increased levels in various disease states (Kruithof et al. 1988
), and has been linked to an increased occurrence of thrombosis in obesity and coronary artery disease (Oseroff et al. 1989
). Defects in PAI-1 are characterized by abnormal bleeding (Takahashi et al. 1996
Goat anti human PAI-1 antibody has been used successfully for the detection of PAI-1 in human tissues by immunohistochemistry, western blotting and ELISA.
- Target Species
- Species Cross-Reactivity
|Target Species||Cross Reactivity|
||Expected from Sequence
||Expected from Sequence
- N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG - liquid
- Antiserum Preparation
- Antisera to human PAI-1 were raised by repeated immunisations of goats with highly purified antigen. Purified IgG was prepared from whole serum by affinity chromatography.
- Buffer Solution
- TRIS buffered saline
- Preservative Stabilisers
|0.5%||Bovine Serum Albumin|
- Peptide with sequence C-GFKIDDKGMAPALRH, corresponding to the internal region of PAI-1 (NP_000593.1).
- Approx. Protein Concentrations
- IgG concentration 0.5 mg/ml
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch.
- Entrez Gene
- GO Terms
chronological cell aging
serine-type endopeptidase activity
serine-type endopeptidase inhibitor activity
defense response to Gram-negative bacterium
regulation of receptor activity
negative regulation of plasminogen activation
negative regulation of smooth muscle cell migration
platelet alpha granule lumen
positive regulation of interleukin-8 production
negative regulation of cell adhesion mediated by integrin
positive regulation of leukotriene production involved in inflammatory response
negative regulation of apoptosis
positive regulation of angiogenesis
positive regulation of receptor-mediated endocytosis
negative regulation of fibrinolysis
negative regulation of vascular wound healing
cellular response to chemical stimulus
cellular response to lipopolysaccharide
positive regulation of monocyte chemotaxis
negative regulation of smooth muscle cell-matrix adhesion
- For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of PAI-1 antibody
|Immunohistology - Paraffin 1
- 1 This antibody requires heat-mediated antigen retrieval prior to staining paraffin sections. Citrate buffer pH6.0 is recommended for this purpose.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Histology Positive Control Tissue
- Human Placenta
- Western Blotting
- Goat anti human PAI-1 detects a band of approximately 45kDa in human duodenum, liver and lung lysates. A minimum incubation time of 1 hour is recommended with this antibody.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Useful Reagents Available
Product Specific References
References for PAI-1 antibody
De Taeye, B. et al. (2005) Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease.
Curr Opin Pharmacol. 5 (2): 149-54.
Berg, D. et al. (2012) Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
J Cell Physiol. 227: 204-12.
Wolff, C. et al. (2011) Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis.
J Pathol. 223: 54-63.
Malinowsky, K. et al. (2014) uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases.
Transl Oncol. 5: 98-104.
Berg, D. et al. (2011) Discovery of new molecular subtypes in oesophageal adenocarcinoma.
PLoS One. 6 (9): e23985.
Lijnen, H.R. (2005) Pleiotropic functions of plasminogen activator inhibitor-1.
J Thromb Haemost. 3 (1): 35-45.